In the last decades, a lot of attention has been paid to the compounds present in medicinal
Cannabis sativa L., such as Δ9‐tetrahydrocannabinol (Δ9‐THC) and cannabidiol (CBD) …

Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …

Introduction: Cannabidiol (CBD) as Epidiolex®(GW Pharmaceuticals) was recently
approved by the US Food and Drug Administration (FDA) to treat rare forms of epilepsy in …

Despite the significant advances in neurology, the cure for neurodegenerative conditions
remains a formidable task to date. Among various factors arising from the complex etiology …

Background Comprehensive literature reviews of historical perspectives and evidence
supporting cannabis/cannabinoids in the treatment of pain, including migraine and …

First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …

Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis
sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders …

Based upon evidence that the therapeutic properties of C annabis preparations are not
solely dependent upon the presence of Δ9‐tetrahydrocannabinol (THC), pharmacological …

Glutamate is an essential excitatory neurotransmitter in the central nervous system, playing
an indispensable role in neuronal development and memory formation. The dysregulation of …

The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a
pharmacological alternative for treating various central nervous system (CNS) disorders …